Optimization algorithms for functional deimmunization of therapeutic proteins

BMC Bioinformatics

Volumn 11, Issue , 2010, Pages

  Parker, Andrew S ^a   Zheng, Wei ^a   Griswold, Karl E ^a,b   Bailey Kellogg, Chris ^a  

^a Dartmouth Department of Computer Science_Dartmouth College   (United States)

^b DARTMOUTH COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN PRESENTING CELLS; GLOBAL OPTIMIZATION ALGORITHM; OPTIMIZATION ALGORITHMS; PROTEIN THERAPEUTICS; SEQUENCE ALIGNMENTS; STABILITY PREDICTION; THERAPEUTIC ACTIVITY; THERAPEUTIC PROTEIN;

ALGORITHMS; AMINO ACIDS; EPITOPES; GLOBAL OPTIMIZATION; IMMUNE SYSTEM; OPTIMIZATION; T-CELLS;

PROTEINS;

EPITOPE; PROTEIN;

ALGORITHM; AMINO ACID SEQUENCE; ARTICLE; BIOLOGY; CHEMISTRY; IMMUNOLOGY; MOLECULAR GENETICS; PROTEIN ENGINEERING; PROTEIN FOLDING;

ALGORITHMS; AMINO ACID SEQUENCE; COMPUTATIONAL BIOLOGY; EPITOPES, T-LYMPHOCYTE; MOLECULAR SEQUENCE DATA; PROTEIN ENGINEERING; PROTEIN FOLDING; PROTEINS;

EID: 77950673538     PISSN: None     EISSN: 14712105     Source Type: Journal    
DOI: 10.1186/1471-2105-11-180     Document Type: Article

References (54)

1. Koren E, Zuckerman LA, Mire-Sluis AR. Immune responses to therapeutic proteins in humans - clinical significance, assessment and prediction. Current Pharmaceutical Biotechnology 2002, 3:349-360. 10.2174/1389201023378175, 12463417.
2. Schellekens H. Immunogenicity of therapeutic proteins: Clinical implications and future prospects. Clinical Therapeutics 2002, 24:1720-1740. 10.1016/S0149-2918(02)80075-3, 12501870.
3. Chirino AJ, Ary ML, Marshall SA. Minimizing the immunogenicity of protein therapeutics. Drug Discovery Today 2004, 9:82-90. 10.1016/S1359-6446(03)02953-2, 15012932.
4. Kessler M, Goldsmith D, Schellekens H. Immunogenicity of biopharmaceuticals. Nephrology, Dialysis, Transplantation 2006, 21:v9-12.
5. Shankar G, Pendley C, Stein KE. A risk-based bioanalytical strategy for the assessment of antibody immune responses against biological drugs. Nature Biotech 2007, 25:555-561.
6. Schellekens H. Bioequivalence and the immunogenicity of biopharmaceuticals. Nature Reviews Drug Discovery 2002, 1:457-462. 10.1038/nrd818, 12119747.
7. De Groot AS, Scott DW. Immunogenicity of protein therapeutics. Trends in Immunology 2007, 28:482-490. 10.1016/j.it.2007.07.011, 17964218.
8. Schellekens H. Factors influencing the immunogenicity of therapeutic proteins. Nephrology, Dialysis, Transplantation 2005, 20:vi3-9.
9. Pradeu T, Carosella ED. On the definition of a criterion of immunogenicity. PNAS 2006, 103:17858-17861. 10.1073/pnas.0608683103, 1693837, 17101995.
10. Morrison SL, Johnson MJ, Herzenberg LA, Oi VT. Chimeric human antibody molecules: Mouse antigen-binding domains with human constant region domains. PNAS 1984, 81:6851-5. 10.1073/pnas.81.21.6851, 392030, 6436822.
11. Jones PT, Dear PH, Foote J, Neuberger MS, Winter G. Replacing the complementarity-determining regions in a human antibody with those from a mouse. Nature 1986, 321:522-525. 10.1038/321522a0, 3713831.
12. Winter G, Harris WJ. Humanized antibodies. Trends in Pharmacological Sciences 1993, 14:139-143. 10.1016/0165-6147(93)90197-R, 8212307.
13. Lo BKC. Antibody humanization by CDR grafting. Methods Mol Biol 2003, 248:135-160.
14. Kashmiri SVS, De Pascalis R, Gonzales NR, Schlom J. SDR grafting - a new approach to antibody humanization. Methods 2005, 36:25-34. 10.1016/j.ymeth.2005.01.003, 15848072.
15. Presta LG. Selection, design, and engineering of therapeutic antibodies. J Allergy and Clinical Immunology 2005, 116:731-736.
16. Hwang WYK, Foote J. Immunogenicity of engineered antibodies. Methods 2005, 36:3-10. 10.1016/j.ymeth.2005.01.001, 15848070.
17. Almagro JC, Fransson J. Humanization of antibodies. Front Biosci 2008, 13:1619-1633.
18. Trombetta ES, Mellman I. Cell biology of antigen processing in vitro and in vivo. Annual Review of Immunology 2005, 23:975-1028. 10.1146/annurev.immunol.22.012703.104538, 15771591.
19. Warmerdam PAM, Plaisance S, Vanderlick K, Vandervoort P, Brepoels K, Collen D, Maeyer MD. Elimination of a human T-cell region in staphylokinase by T-cell screening and computer modeling. J Thromb Haemost 2002, 87:666-673.
20. Jones TD, Phillips WJ, Smith BJ, Bamford CA, Nayee PD, Baglin TP, Gaston JSH, Baker MP. Identification and removal of a promiscuous CD4+ T cell epitope from the C1 domain of factor VIII. J Thromb Haemost 2005, 3:991-1000. 10.1111/j.1538-7836.2005.01309.x, 15869596.
21. Harding FA, Liu AD, Stickler M, Razo OJ, Chin R, Faravashi N, Viola W, Graycar T, Yeung VP, Aehle W, Meijer D, Wong S, Rashid MH, Valdes AM, Schellenberger V. A beta-lactamase with reduced immunogenicity for the targeted delivery of chemotherapeutics using antibody-directed enzyme prodrug therapy. Mol Cancer Ther 2005, 4:1791-1800. 10.1158/1535-7163.MCT-05-0189, 16276001.
22. Tangri S, Mothe BR, Eisenbraun J, Sidney J, Southwood S, Briggs K, Zinckgraf J, Bilsel P, Newman M, Chesnut R, LiCalsi C, Sette A. Rationally engineered therapeutic proteins with reduced immunogenicity. J Immunol 2005, 174:3187-3196.
23. Lazar GA, Desjarlais JR, Jacinto J, Karki S, Hammond PW. A molecular immunology approach to antibody humanization and functional optimization. Mol Immunol 2007, 44:1986-1998. 10.1016/j.molimm.2006.09.029, 17079018.
24. De Groot AS, Moise L. Prediction of immunogenicity for therapeutic proteins: State of the art. Curr Opin Drug Discov Devel 2007, 10:332-340.
25. Wang P, Sidney J, Dow C, Mothe B, Sette A, Peters B. A systematic assessment of MHC class II peptide binding predictions and evaluation of a consensus approach. PLoS Comp Biol 2008, 4:e1000048.
26. De Groot AS, Martin W. Reducing risk, improving outcomes: Bioengineering less immunogenic protein therapeutics. Clinical Immunology 2009, 131:189-201. 10.1016/j.clim.2009.01.009, 19269256.
27. De Groot AS, Knopp PM, Martin W. De-immunization of therapeutic proteins by T-cell epitope modification. Dev Biol (Basel) 2005, 122:171-94.
28. Koren E, De Groot AS, Jawa V, Beck KD, Boone T, Rivera D, Li L, Mytych D, Koscec M, Weeraratne D, Swanson S, Martin W. Clinical validation of the "in silico" prediction of immunogenicity of a human recombinant therapeutic protein. Clinical Immunology 2007, 124:26-32. 10.1016/j.clim.2007.03.544, 17490912.
29. Singh H, Raghava G. ProPred: prediction of HLA-DR binding sites. Bioinformatics 2001, 17:1236-1237. 10.1093/bioinformatics/17.12.1236, 11751237.
30. Nielsen M, Lundegaard C, Lund O. Prediction of MHC class II binding affinity using SMM-align, a novel stabilization matrix alignment method. BMC Bioinformatics 2007, 8:238. 10.1186/1471-2105-8-238, 1939856, 17608956.
31. Guang LZ, Khan AM, Srinivasan KN, August JT, Brusic V. MULTIPRED: a computational system for prediction of promiscuous HLA binding peptides. Nucl Acids Res 2005, 33:W172-W179. 10.1093/nar/gki506, 1160213, 15980449.
32. Bui HH, Sidney J, Peters B, Sathiamurthy M, Sinichi A, Purton KA, Mothe BR, Chisari FV, Watkins DI, Sette A. Automated generation and evaluation of specific MHC binding predictive tools: ARB matrix applications. Immunogenetics 2005, 57:304-314. 10.1007/s00251-005-0798-y, 15868141.
33. Schirle M, Weinschenk T, Stevanovic S. Combining computer algorithms with experimental approaches permits the rapid and accurate identification of T cell epitopes from defined antigens. J Immunological Methods 2001, 257:1-16.
34. Sturniolo T, Bono E, Ding J, Raddrizzani L, Tuereci O, Sahin U, Braxenthaler M, Gallazzi F, Protti MP, Sinigaglia F, Hammer J. Generation of tissue-specific and promiscuous HLA ligand database using DNA microarrays and virtual HLA class II matrices. Nature Biotechnol 1999, 17:555-561.
35. Dinglasan RR, Kalume DE, Kanzok SM, Ghosh AK, Muratova O, Pandey A, Jacobs-Lorena M. Disruption of Plasmodium falciparum development by antibodies against a conserved mosquito midgut antigen. PNAS 2007, 104:13461-13466. 10.1073/pnas.0702239104, 1948931, 17673553.
36. Klyushnenkova EN, Kouiavskaia DV, Kodak JA, Vandenbark AA, Alexander RB. Identification of HLA-DRB1*1501-restricted T-cell epitopes from human prostatic acid phosphatase. Prostate 2007, 67:1019-1028. 10.1002/pros.20575, 17455230.
37. Mustafa AS, Shaban FA. ProPred analysis and experimental evaluation of promiscuous T-cell epitopes of three major secreted antigens of Mycobacterium tuberculosis. Tuberculosis 2006, 86:115-124. 10.1016/j.tube.2005.05.001, 16039905.
38. Peters B, Sidney J, Bourne P, Bui HH, Buus S, Doh G, Fleri W, Kronenberg M, Kubo R, Lund O, Nemazee D, Ponomarenko JV, Sathiamurthy M, Schoenberger S, Stewart S, Surko P, Way S, Wilson S, Sette A. The immune epitope database and analysis resource: from vision to blueprint. PLoS Biol 2005, 3:e91. 10.1371/journal.pbio.0030091, 1065705, 15760272.
39. Rammensee H, Bachmann J, Emmerich NP, Bachor OA, Stevanovic S. SYFPEITHI: database for MHC ligands and peptide motifs. Immunogenetics 1999, 50:213-219. 10.1007/s002510050595, 10602881.
40. Southwood S, Sidney J, Kondo A, del Guercio MF, Appella E, Hoffman S, Kubo RT, Chesnut RW, Grey HM, Sette A. Several common HLA-DR types share largely overlapping peptide binding repertoires. J Immunol 1998, 160:3363-3373.
41. Henikoff S, Henikoff JG. Amino acid substitutions from protein blocks. PNAS 1992, 89:10915-10919. 10.1073/pnas.89.22.10915, 50453, 1438297.
42. Ohage E, Steipe B. Intrabody construction and expression. I. The critical role of VL domain stability. J Mol Biol 1999, 291:1119-1128. 10.1006/jmbi.1999.3019, 10518947.
43. Nikolova PV, Henckel J, Lane DP, Fersht AR. Semirational design of active tumor suppressor p53 DNA binding domain with enhanced stability. PNAS 1998, 95:14675-14680. 10.1073/pnas.95.25.14675, 24508, 9843948.
44. Wang Q, Buckle AM, Fersht AR. Stabilization of GroEL minichaperones by core and surface mutations. J Mol Biol 2000, 298:917-926. 10.1006/jmbi.2000.3716, 10801358.
45. Lehmann M, Pasamontes L, Lassen SF, Wyss M. The consensus concept for thermostability engineering of proteins. Biochim Biophys Acta 2000, 1543:408-415.
46. Lehmann M, Loch C, Middendort A, Studer D, Lassen SF, Pasamontes L, van Loon APGM, Wyss M. The consensus concept for thermostability engineering of proteins: further proof of concept. Protein Eng 2002, 15:403-411. 10.1093/protein/15.5.403, 12034860.
47. Gerstein M, Sonnhammer ELL, Chothia C. Volume changes in protein evolution. J Mol Biol 1994, 236:1067-1078. 10.1016/0022-2836(94)90012-4, 8120887.
48. Guerois R, Nielsen JE, Serrano L. Predicting changes in the stability of proteins and protein complexes: a study of more than 1000 mutations. J Mol Biol 2002, 320:369-387. 10.1016/S0022-2836(02)00442-4, 12079393.
49. Fajardo-Sanchez E, Stricher F, Paques F, Isalan M, Serrano L. Computer design of obligate heterodimer meganucleases allows efficient cutting of custom DNA sequences. Nucl Acids Res 2008, 36:2163-2173. 10.1093/nar/gkn059, 2367722, 18276641.
50. Sloot AM, Tur V, Szegezdi E, Mullally MM, Cool RH, Samali A, Serrano L, Quax WJ. Designed tumor necrosis factor-related apoptosis-inducing ligand variants initiating apoptosis exclusively via the DR5 receptor. PNAS 2006, 103:8634-8639. 10.1073/pnas.0510187103, 1482632, 16731632.
51. Bellman R, Kalaba R. On the Kth best policies. J SIAM 1960, 8:582-588.
52. Waterman MS, Byers TH. A dynamic programming algorithm to find all solutions in a neighborhood of the optimum. Math Biosci 1985, 77:179-188.
53. Naor D, Brutlag D. On near-optimal alignments in biological sequences. J Comp Biol 1994, 1:349-366.
54. Gusfield D, Balasubramanian K, Naor D. Parametric optimization of sequence alignment. Algorithmica 1994, 12:312-326.